Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Canada has been experiencing steady growth over the past few years.
Customer preferences: Patients suffering from rheumatoid arthritis and other autoimmune diseases are increasingly seeking out effective treatments to manage their symptoms and improve their quality of life. As a result, there is a growing demand for anti-rheumatic drugs in Canada. Patients are also becoming more aware of the different treatment options available to them and are willing to try new medications to find the best fit for their needs.
Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Canada is the increasing use of biologic drugs. These medications are designed to target specific components of the immune system and have been shown to be highly effective in managing symptoms of rheumatoid arthritis and other autoimmune diseases. As a result, biologic drugs have become a popular choice among patients and healthcare providers.Another trend in the market is the growing availability of biosimilars. Biosimilars are drugs that are similar to biologics but are manufactured by different companies. They are often less expensive than their brand-name counterparts and are becoming increasingly popular in Canada as more biosimilars are approved for use.
Local special circumstances: One of the unique aspects of the Anti-Rheumatic Drugs market in Canada is the country's public healthcare system. The Canadian government provides universal healthcare coverage to all citizens, which includes coverage for many anti-rheumatic drugs. This has helped to make these medications more accessible to patients who may not be able to afford them otherwise.
Underlying macroeconomic factors: The Canadian economy has been relatively stable in recent years, which has helped to support growth in the Anti-Rheumatic Drugs market. In addition, the country's aging population has contributed to the increasing demand for these medications, as older adults are more likely to develop rheumatoid arthritis and other autoimmune diseases. The Canadian government has also taken steps to promote innovation in the healthcare sector, which has helped to drive the development of new and more effective anti-rheumatic drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
